The emergence of new obesity medications has renewed interest in managing obesity among older adults over the age of 60. Obesity, defined as a body mass index (BMI) greater than 30 kg/m2, affects more than 40% of older adults [1] and leads to an increased risk of falls, chronic diseases, and long-term disability [2–8]. In later life, obesity is also associated with a lower quality of life and a higher likelihood of frailty, a condition marked by increased vulnerability to stressors and adverse outcomes [9–11]. Moreover, the psychosocial context, along with polypharmacy and multimorbidity, adds complexity to clinical decision-making, underscoring the biological and clinical heterogeneity of this population group.
Given the shortage of geriatric care providers and the even smaller number trained in both geriatrics and obesity medicine, there is a pressing need to address the unique challenges faced by older adults with obesity. A multidisciplinary team approach, involving registered dietitians, physical therapists or exercise scientists, care managers, social workers, and clinicians, offers a more holistic, rather than disease-centric, framework for care. These teams are well positioned to prioritize function-based outcomes alongside traditional metrics like weight. Central to this approach is the cornerstone of geriatric medicine, “first do no harm,” which is especially important when considering risks such as weight loss-induced sarcopenia, bone loss, and the potential onset of frailty. The special issue of Obesity aims to highlight key aspects of geriatric obesity across the aging spectrum and provide clinicians with practical guidance for managing this complex population. In doing so, it not only identifies critical research gaps and mechanisms underlying aging-related outcomes but also offers actionable insights for everyday clinical practice.
The issue includes Dong et al.’s [12] analysis of data from the National Health and Nutrition Examination Survey. Although cross-sectional, this study advances the conversation beyond chronological aging by examining the relationship between biological aging and biomarkers, specifically estradiol and body roundness index. Biological aging, a central concept in geroscience, focuses on slowing the aging process [13]. Unlike traditional anthropometric measures, the body roundness index shows strong predictive validity for both visceral and total body fat [14]. Dong et al. found robust independent associations and notable synergy between these biomarkers when modeled together, suggesting meaningful biological implications. In another study using data from the Minnesota Twin Registry, Freilich et al. explored how personality domains in early-to-midadulthood predict later-life metabolic outcomes [15]. The study revealed that emotional instability, particularly alienation and stress reactivity, was significantly associated with adverse metabolic profiles. Genetic correlations also appeared additive, especially in relation to measures of obesity. Together, these findings highlight the value of integrating biomarker, behavioral, and environmental data into routine practice. They also pave the way for future longitudinal studies and targeted interventions aimed at improving outcomes in older adults with obesity.
Cognitive outcomes are important concerns in geriatrics, with dementia affecting ~11% of adults over age 65 [16]. Two studies in this issue, one by Flores et al. [17] and another by Mongraw-Chaffin et al. [18], offer differing perspectives using data from the National Health and Aging Trends Survey and the Look AHEAD extension study, respectively. Flores et al. examined weight variability using traditional anthropometric measures such as BMI and weight circumference, assessing their impact on cognitive trajectories. In contrast, Mongraw-Chaffin et al. focused on body composition trajectories, specifically fat and appendicular lean mass. Flores et al. found that weight cycling and weight loss of 5% or more were associated with declines in cognitive function, even after adjusting for grip strength and the intentionality of weight loss. Conversely, the Look AHEAD study showed that gradual reductions in total fat were associated with more modest changes in cognitive performance. A notable strength of Mongraw-Chaffin et al.’s study was the inclusion of appendicular lean mass as a proxy for sarcopenia, now defined as the age-related loss of muscle mass and strength [19]. Sarcopenia is highly prevalent among older adults and, when combined with obesity, can lead to sarcopenic obesity, a condition associated with worse health outcomes [20, 21]. Importantly, both studies found that adjusting for demographic characteristics attenuated the strength of their models. Together, these findings demonstrate the gaps in our understanding of how obesity affects cognitive function in older adults. They raise important questions about the potential for primary prevention and a need for long-term observational and interventional studies that account for outcome heterogeneity. These insights also have implications for evaluating whether newer incretin mimetic agents should be studied more rigorously in this population.
The systematic review by Chen et al. [22] is especially timely given the emergence of new obesity therapeutics. Although the analysis included only six studies, just one each on semaglutide and tirzepatide, all demonstrated weight reduction. However, the authors noted a significant gap; limited data was specific to older adults. Few studies reported adverse events, which are known to be more common in this population based on observational and real-world evidence [23, 24]. This raises a critical question: how should clinicians proceed? To help address this gap, this issue includes several narrative reviews aimed at guiding obesity medicine providers. Pendry and Sevilla-Martir’s review outlines the various classes of obesity medicines and highlights data relevant to older adults [25]. Dewar, drawing on expertise as a geriatrics-trained obesity medicine clinician within an interdisciplinary clinic [26], provides a comprehensive framework for managing older patients, offering practical guidance for care teams [27]. A recurring theme across these reviews is the limited diagnostic accuracy of BMI in older adults [28]. To address this, Banack et al. introduce a novel approach using BMI-for-age percentiles, which may offer clinicians and researchers a more precise method for identifying appropriate candidates for targeted interventions [29].
Lifestyle-based interventions remain a cornerstone of multidisciplinary care for older adults with obesity. Supported by expert consensus, they are essential for balancing the risks and benefits of weight loss [19]. One key challenge is managing the loss of muscle and bone mass that can accompany fat reduction, especially given the risk of fat regain over time. Despite the growing availability of obesity medicines and the recognition of ICD-10 codes for sarcopenia [30], routine assessment of body composition is still not widely integrated into clinical practice in the United States. Lynch et al.’s study highlights the translational potential of using automated algorithms to analyze body composition compartments via computed tomography, a tool already used in many clinical settings [31]. Their findings show that radiomics can effectively differentiate between fat, muscle, and bone and correlate strongly with DXA-based measures. Cortes et al. [32] further contribute by reviewing the benefits and risks of intentional weight loss in older adults. Together, these studies demonstrate opportunities for continued research and innovation in clinical care strategies for this population.
This collection of articles lays a foundation for advancing both the science and clinical practice of obesity management in older adults. The field is rapidly evolving, and the opportunities are abundant. First, there is a need for geroscience-informed biomarkers that go beyond those currently used in routine clinical care. Integrating these biomarkers with body composition metrics and leveraging advanced data science techniques could deepen our understanding of aging-related physiological changes and shift clinical paradigms from age-centric to biology-centric models. Such research will also clarify how modifiable and non-modifiable factors influence body composition trajectories and can identify new targets to intervene. Second, the emergence of novel obesity medications places us at a critical juncture. While these therapies hold promise, their use in older adults is often guided by data derived from younger populations, limiting generalizability. This does not suggest that older adults should be excluded from treatment, but rather that clinicians must apply core geriatric principles of “start low, go slow” and proceed with caution. There is an urgent need for research to understand the natural history, adverse event profiles, and geriatric-specific outcomes associated with these medications. Third, the relationship between late-life obesity and cognitive function remains poorly defined, despite its importance as a major public health concern. Future studies should consider the rate of weight loss using DXA-based measures and explore how existing clinical imaging data can be repurposed to assess body composition. Radiomics, which applies artificial intelligence-based algorithms to analyze imaging data, holds great promise for integration into electronic health records and routine care. Finally, the implications of these studies converge on the syndrome of sarcopenic obesity, which has gained attention with the advent of newer incretin mimetic drugs. Emerging therapies, such as activin receptor blockers [33] and myostatin inhibitors [34], may not only transform obesity treatment but also extend to related syndromes including sarcopenia, frailty, and malnutrition.
While this collection represents only a fraction of the exciting work under way in aging and obesity, it highlights the rapid pace of innovation—from new pharmacological therapies to artificial intelligence-driven methodologies—and the implementation challenges that lie ahead. We are still a decade or more away from the routine clinical use of biological age assessments, such as epigenetic clocks or multi-omics platforms. Yet, imagine a future where clinicians can evaluate a patient’s biological and clinical phenotype to tailor treatments that optimize physical function while minimizing the loss of muscle mass and strength. That future is approaching quickly. As new discoveries continue to emerge, awareness is not enough… we must be prepared to act on them.
Funding:
Dr. John A. Batsis’ research reported in this publication was supported in part by the National Institute on Aging under Award Number R01AG077163–01A1, the North Carolina Translational and Clinical Sciences (NC TraCS) Institute, University of North Carolina at Chapel Hill, which is supported by the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, through Grant Award Number UL1TR002489, the University of North Carolina at Chapel Hill Center for Aging and Health, and the Nutrition Obesity Research Center supported by the National Institute of Diabetes and Digestive and Kidney Diseases (P30-DK056350).
Footnotes
Conflicts of Interest
Dr. John A. Batsis owns equity in SynchroHealth LLC and provides consultation to Abbott Nutrition and Regeneron. The author declares no conflicts of interest.
Disclosure
The content is solely the responsibility of the author and does not necessarily represent the official views of the National Institutes of Health.
Data Availability Statement
Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.
References
- 1.Hales CM, Carroll MD, Fryar CD, and Ogden CL, “Prevalence of Obesity and Severe Obesity Among Adults: United States, 2017–2018,” NCHS Data Brief no. 360 (2020): 1–8. [PubMed] [Google Scholar]
- 2.American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity, “Guiding Principles for the Care of Older Adults With Multimorbidity: An Approach for Clinicians: American Geriatrics Society Expert Panel on the Care of Older Adults With Multimorbidity,” Journal of the American Geriatrics Society 60, no. 10 (2012): E1–E25. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Jensen GL and Friedmann JM, “Obesity Is Associated With Functional Decline in Community-Dwelling Rural Older Persons,” Journal of the American Geriatrics Society 50, no. 5 (2002): 918–923. [DOI] [PubMed] [Google Scholar]
- 4.Hu F, Xu L, Zhou J, Zhang J, Gao Z, and Hong Z, “Association Between Overweight, Obesity and the Prevalence of Multimorbidity Among the Elderly: Evidence From a Cross-Sectional Analysis in Shandong, China,” International Journal of Environmental Research and Public Health 17, no. 22 (2020): 8355. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Ryan A, Wallace E, O’Hara P, and Smith SM, “Multimorbidity and Functional Decline in Community-Dwelling Adults: A Systematic Review,” Health and Quality of Life Outcomes 13 (2015): 168. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Flegal KM, Kit BK, Orpana H, and Graubard BI, “Association of All-Cause Mortality With Overweight and Obesity Using Standard Body Mass Index Categories: A Systematic Review and Meta-Analysis,” JAMA 309, no. 1 (2013): 71–82. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Zizza CA, Herring A, Stevens J, and Popkin BM, “Obesity Affects Nursing-Care Facility Admission Among Whites but Not Blacks,” Obesity Research 10, no. 8 (2002): 816–823. [DOI] [PubMed] [Google Scholar]
- 8.Zhang N, Li Y, Rodriguez-Monguio R, Barenberg A, Temkin-Greener H, and Gurwitz J, “Are Obese Residents More Likely to be Admitted to Nursing Homes That Have More Deficiencies in Care?,” Journal of the American Geriatrics Society 64, no. 5 (2016): 1085–1090. [DOI] [PubMed] [Google Scholar]
- 9.Ferrucci L and Kuchel GA, “Heterogeneity of Aging: Individual Risk Factors, Mechanisms, Patient Priorities, and Outcomes,” Journal of the American Geriatrics Society 69 (2021): 610–612. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Kennedy BK, Berger SL, Brunet A, et al. , “Geroscience: Linking Aging to Chronic Disease,” Cell 159, no. 4 (2014): 709–713. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Burch JB, Augustine AD, Frieden LA, et al. , “Advances in Geroscience: Impact on Healthspan and Chronic Disease,” Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 69, no. S1 (2014): S1–S3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Dong F, Ma Y, and Chen XF, “Synergistic Association of Estradiol and Body Roundness Index With Accelerated Biological Aging in Male Individuals,” Obesity (Silver Spring) (2025), 10.1002/oby.24326. [DOI] [PubMed] [Google Scholar]
- 13.Kritchevsky SB and Cummings SR, “Geroscience: A Translational Review,” JAMA 334, no. 12 (2025): 1094–1102, 10.1001/jama.2025.11289. [DOI] [PubMed] [Google Scholar]
- 14.Calderón-García JF, Roncero-Martín R, Rico-Martín S, et al. , “Effectiveness of Body Roundness Index (BRI) and a Body Shape Index (ABSI) in Predicting Hypertension: A Systematic Review and Meta-Analysis of Observational Studies,” International Journal of Environmental Research and Public Health 18, no. 21 (2021): 11607. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Freilich CD, Kunkel JJ, Dugan KA, et al. , “Genetic and Environmental Contributions to the Associations Between Midlife Personality and Late-Life Metabolic Health,” Obesity (Silver Spring) (2025), 10.1002/oby.24268. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Rajan KB, Weuve J, Barnes LL, McAninch EA, Wilson RS, and Evans DA, “Population Estimate of People With Clinical Alzheimer’s Disease and Mild Cognitive Impairment in the United States (2020–2060),” Alzheimer’s & Dementia 17, no. 12 (2021): 1966–1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Flores AC, Wennberg AM, Leung CW, and Na M, “Variability in Body Weight and Body Composition and Cognitive Trajectories in Older Adults in the United States,” Obesity (Silver Spring) (2025), 10.1002/oby.24309. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Mongraw-Chaffin M, Evans JK, Shappell HM, Espeland MA, and Hayden KM, “Association of Body Composition Trajectories With Changes in Cognitive Performance in the Look AHEAD Study,” Obesity (Silver Spring) (2025), 10.1002/oby.24212. [DOI] [PubMed] [Google Scholar]
- 19.Kirk B, Cawthon PM, Arai H, et al. , “The Conceptual Definition of Sarcopenia: Delphi Consensus From the Global Leadership Initiative in Sarcopenia (GLIS),” Age and Ageing 53, no. 3 (2024): afae052. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Prado CM, Batsis JA, Donini LM, Gonzalez MC, and Siervo M, “Sarcopenic Obesity in Older Adults: A Clinical Overview,” Nature Reviews. Endocrinology 20, no. 5 (2024): 261–277. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Batsis JA and Villareal DT, “Sarcopenic Obesity in Older Adults: Aetiology, Epidemiology and Treatment Strategies,” Nature Reviews. Endocrinology 14, no. 9 (2018): 513–537. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Chen AS, Hajduk AM, Grimshaw AA, Fried TR, Jastreboff AM, and Lipska KJ, “Efficacy of Antiobesity Medications for Weight Reduction in Older Adults: A Systematic Review,” Obesity (Silver Spring) (2024), 10.1002/oby.24160. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Warren M, Chaykin L, Trachtenbarg D, Nayak G, Wijayasinghe N, and Cariou B, “Semaglutide as a Therapeutic Option for Elderly Patients With Type 2 Diabetes: Pooled Analysis of the SUSTAIN 1–5 Trials,” Diabetes, Obesity & Metabolism 20, no. 9 (2018): 2291–2297. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Karagiannis T, Malandris K, Avgerinos I, et al. , “Subcutaneously Administered Tirzepatide vs Semaglutide for Adults With Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials,” Diabetologia 67 (2024): 1206–1222. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Pendrey A and Sevilla-Martir J, “Antiobesity Medications for Older Adults—The New, the Good, the Bad, and the Unknown,” Obesity (Silver Spring) (2025), 10.1002/oby.70029. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Dewar S, Janevic MR, Batsis JA, and Alexander NB, “Older Adults With Obesity: Need for 4Ms Age-Friendly Approach to Care,” Journal of the American Geriatrics Society 73, no. 5 (2025): 1621–1623. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Dewar S, “A Geriatrician’s Approach to Managing the Complex Older Adult With Obesity,” Obesity (Silver Spring) (2025), 10.1002/oby.24267. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Batsis JA, Mackenzie TA, Bartels SJ, Sahakyan KR, Somers VK, and Lopez-Jimenez F, “Diagnostic Accuracy of Body Mass Index to Identify Obesity in Older Adults: NHANES 1999–2004,” International Journal of Obesity 40, no. 5 (2016): 761–767. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Banack HR, Kim CD, Cook CE, Wasser A, Kaufman JS, and Stovitz SD, “BMI-For-Age Percentile Curves for Older Adults,” Obesity (Silver Spring) (2025), 10.1002/oby.24189. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Anker SD, Morley JE, and Von Haehling S, “Welcome to the ICD-10 Code for Sarcopenia,” Journal of Cachexia, Sarcopenia and Muscle 7, no. 5 (2016): 512–514. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Lynch SD, Howard M, Beavers DP, et al. , “Musculoskeletal Characteristics in Older Adults With Overweight or Obesity: INVEST in Bone Health Trial Baseline Analysis,” Obesity (Silver Spring) (2025), 10.1002/oby.24243. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Cortes TM, Chae K, Foy CM, Houston DK, and Beavers KM, “The Impact of Lifestyle-Based Weight Loss in Older Adults With Obesity on Muscle and Bone Health: A Balancing Act,” Obesity (Silver Spring) (2025), 10.1002/oby.24229. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Heymsfield SB, Coleman LA, Miller R, et al. , “Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial,” JAMA Network Open 4, no. 1 (2021): e2033457. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Wetzlich B, Nyakundi BB, and Yang J, “Therapeutic Applications and Challenges in Myostatin Inhibition for Enhanced Skeletal Muscle Mass and Functions,” Molecular and Cellular Biochemistry 480, no. 3 (2025): 1535–1553. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.
